Stark H - Search Results

1

BOPPY-based novel fluorescent dopamine D₂ and D₃ receptor ligands.

Elek M, Dubiel M, Mayer L, Zivkovic A, Müller TJJ, Stark H. Elek M, et al. Among authors: stark h. Bioorg Med Chem Lett. 2022 Mar 1;59:128573. doi: 10.1016/j.bmcl.2022.128573. Epub 2022 Jan 19. Bioorg Med Chem Lett. 2022. PMID: 35063632

2

Analogues and derivatives of ciproxifan, a novel prototype for generating potent histamine H3-receptor antagonists.

Stark H, Ligneau X, Sadek B, Ganellin CR, Arrang JM, Schwartz JC, Schunack W. Stark H, et al. Bioorg Med Chem Lett. 2000 Oct 16;10(20):2379-82. doi: 10.1016/s0960-894x(00)00473-x. Bioorg Med Chem Lett. 2000. PMID: 11055360

3

N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands.

Hackling A, Ghosh R, Perachon S, Mann A, Höltje HD, Wermuth CG, Schwartz JC, Sippl W, Sokoloff P, Stark H. Hackling A, et al. Among authors: stark h. J Med Chem. 2003 Aug 28;46(18):3883-99. doi: 10.1021/jm030836n. J Med Chem. 2003. PMID: 12930150

4

Parallel synthesis and dopamine D3/D2 receptor screening of novel {4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}carboxamides.

Heidler P, Zohrabi-Kalantari V, Calmels T, Capet M, Berrebi-Bertrand I, Schwartz JC, Stark H, Link A. Heidler P, et al. Among authors: stark h. Bioorg Med Chem. 2005 Mar 15;13(6):2009-14. doi: 10.1016/j.bmc.2005.01.018. Bioorg Med Chem. 2005. PMID: 15727854

5

Fluorescent non-imidazole histamine H3 receptor ligands with nanomolar affinities.

Amon M, Ligneau X, Schwartz JC, Stark H. Amon M, et al. Among authors: stark h. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1938-40. doi: 10.1016/j.bmcl.2005.12.084. Epub 2006 Jan 24. Bioorg Med Chem Lett. 2006. PMID: 16434192

6

N-(4-(4-(2-Halogenophenyl)piperazin-1-yl)butyl) substituted cinnamoyl amide derivatives as dopamine D2 and D3 receptor ligands.

Saur O, Hackling AE, Perachon S, Schwartz JC, Sokoloff P, Stark H. Saur O, et al. Among authors: stark h. Arch Pharm (Weinheim). 2007 Apr;340(4):178-84. doi: 10.1002/ardp.200600196. Arch Pharm (Weinheim). 2007. PMID: 17405129

7

Hybrid approach for the design of highly affine and selective dopamine D(3) receptor ligands using privileged scaffolds of biogenic amine GPCR ligands.

Sasse BC, Mach UR, Leppaenen J, Calmels T, Stark H. Sasse BC, et al. Among authors: stark h. Bioorg Med Chem. 2007 Dec 1;15(23):7258-73. doi: 10.1016/j.bmc.2007.08.034. Epub 2007 Aug 25. Bioorg Med Chem. 2007. PMID: 17826096

8

A solid phase parallel synthesis of diverse amides as dopamine D3 receptor ligands.

Jean M, Renault J, Camelin JC, Levoin N, Danvy D, Stark H, Capet M, Uriac P. Jean M, et al. Among authors: stark h. J Enzyme Inhib Med Chem. 2008 Oct;23(5):588-92. doi: 10.1080/14756360701830023. J Enzyme Inhib Med Chem. 2008. PMID: 18608769

9

Acidic elements in histamine H(3) receptor antagonists.

Sander K, von Coburg Y, Camelin JC, Ligneau X, Rau O, Schubert-Zsilavecz M, Schwartz JC, Stark H. Sander K, et al. Among authors: stark h. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1581-4. doi: 10.1016/j.bmcl.2010.01.089. Epub 2010 Jan 21. Bioorg Med Chem Lett. 2010. PMID: 20138762

10

Azole derivatives as histamine H3 receptor antagonists, part I: thiazol-2-yl ethers.

Walter M, von Coburg Y, Isensee K, Sander K, Ligneau X, Camelin JC, Schwartz JC, Stark H. Walter M, et al. Among authors: stark h. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5879-82. doi: 10.1016/j.bmcl.2010.07.098. Epub 2010 Aug 1. Bioorg Med Chem Lett. 2010. PMID: 20728354

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,174 results

Search Page